PD-L1 Checkpoint Blockade Prevents Immune Dysfunction and Leukemia Development in a Mouse Model of Chronic Lymphocytic Leukemia
Menée à l'aide de modèles murins, cette étude met en évidence des mécanismes par lesquels une immunothérapie anti PD-L1 prévient le développement d'une leucémie lymphocytaire chronique
Blood, sous presse, 2015, résumé
Résumé en anglais
Blockade of the PD-1/PD-L1 immune checkpoint augments anti-tumor immunity and induces durable responses in patients with solid cancers, but data on clinical efficacy in leukemias is largely missing. Chronic lymphocytic leukemia (CLL) is associated with a tumor-supportive microenvironment and a dysfunctional immune system, as shown by "exhausted" T cells, defective immunological synapse formation, and immunosuppressive myeloid cells. These defects involve aberrant expression of PD-L1 and are closely mirrored in the E
